A trial of topiramate for patients with hereditary spinocerebellar ataxia

Shiroh Miura; Ryusuke Sawada; Akiko Yorita; Hiroshi Kida; Takashi Kamada; Yoshihiro Yamanishi

doi:10.1002/ccr3.6980

A trial of topiramate for patients with hereditary spinocerebellar ataxia

Clin Case Rep. 2023 Feb 26;11(2):e6980. doi: 10.1002/ccr3.6980. eCollection 2023 Feb.

Authors

Shiroh Miura¹, Ryusuke Sawada², Akiko Yorita³, Hiroshi Kida⁴, Takashi Kamada⁵, Yoshihiro Yamanishi⁶

Affiliations

¹ Department of Neurology and Geriatric Medicine Ehime University Graduate School of Medicine Toon Ehime Japan.
² Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kita-ku Okayama Japan.
³ Division of Respirology, Neurology and Rheumatology, Department of Medicine Kurume University School of Medicine Kurume Fukuoka Japan.
⁴ Department of Anatomy Fukuoka University School of Medicine Jonan-ku Fukuoka Japan.
⁵ Department of Neurology Fukuoka Sanno Hospital Sawara-ku Fukuoka Japan.
⁶ Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering Kyushu Institute of Technology Iizuka Fukuoka Japan.

Abstract

In an open pilot trial, six patients with various hereditary forms of spinocerebellar ataxia (SCA) were assigned to topiramate (50 mg/day) for 24 weeks. Four patients completed the protocol without adverse events. Of these four patients, topiramate was effective for three patients. Some patients with SCA could respond to treatment with topiramate.

Keywords: drug repositioning; spinocerebellar ataxia; topiramate.

Publication types

Case Reports